Littérature scientifique sur le sujet « Metastatic papillary renal-Cell cancer »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Metastatic papillary renal-Cell cancer ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "Metastatic papillary renal-Cell cancer"
Sidana, Abhinav, Amit L. Jain, Meet Kadakia, Spencer Krane, Julia C. Friend, Akhil Muthigi, Martha Ninos, Joanna H. Shih et Ramaprasad Srinivasan. « Predictors of mortality in metastatic papillary renal cell cancer. » Journal of Clinical Oncology 35, no 6_suppl (20 février 2017) : 509. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.509.
Texte intégralCarlo, Maria Isabel, Nabeela Khan, Yingbei Chen, James Hsieh, A. Ari Hakimi, Chung-Han Lee, Darren R. Feldman, Robert J. Motzer et Martin Henner Voss. « The genomic landscape of metastatic non-clear cell renal cell carcinoma. » Journal of Clinical Oncology 35, no 6_suppl (20 février 2017) : 474. http://dx.doi.org/10.1200/jco.2017.35.6_suppl.474.
Texte intégralGraham, Jeffrey, Connor Wells, Frede Donskov, Jae-Lyun Lee, Anna Paola Fraccon, Felice Pasini, Camillo Porta et al. « Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). » Journal of Clinical Oncology 36, no 6_suppl (20 février 2018) : 581. http://dx.doi.org/10.1200/jco.2018.36.6_suppl.581.
Texte intégralDudani, Shaan, Guillermo de Velasco, Connor Wells, Chun Loo Gan, Frede Donskov, Camillo Porta, Anna Fraccon et al. « Characterizing sites of metastatic involvement in metastatic clear-cell, papillary, and chromophobe renal cell carcinoma. » Journal of Clinical Oncology 38, no 15_suppl (20 mai 2020) : 5071. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5071.
Texte intégralMotzer, Robert J., Jennifer Bacik, Tania Mariani, Paul Russo, Madhu Mazumdar et Victor Reuter. « Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology ». Journal of Clinical Oncology 20, no 9 (1 mai 2002) : 2376–81. http://dx.doi.org/10.1200/jco.2002.11.123.
Texte intégralRonnen, Ellen A., G. Varuni Kondagunta, Nicole Ishill, Lesley Spodek, Paul Russo, Victor Reuter, Jennifer Bacik et Robert J. Motzer. « Treatment outcome for metastatic papillary renal cell carcinoma patients ». Cancer 107, no 11 (2006) : 2617–21. http://dx.doi.org/10.1002/cncr.22340.
Texte intégralElabbady, Ahmed, Ryan Boudreau et Vahid Mehrnoush. « Rapid metachronous bladder metastasis of type 2 papillary renal cell carcinoma ». Archive of Clinical Cases 10, no 2 (18 mai 2023) : 93–96. http://dx.doi.org/10.22551/2023.39.1002.10249.
Texte intégralSteiner, T., J. Roigas, H. Kirchner, C. Doehn, H. Heynemann, M. Siebels, S. Loening et al. « Clinical course of patients with metastatic papillary renal cell carcinoma ». Journal of Clinical Oncology 24, no 18_suppl (20 juin 2006) : 14591. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.14591.
Texte intégralYonese, Ichiro, Masaya Ito, Kosuke Takemura, Takao Kamai et Fumitaka Koga. « A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy ». Journal of Kidney Cancer and VHL 7, no 2 (20 juillet 2020) : 6–10. http://dx.doi.org/10.15586/jkcvhl.2020.148.
Texte intégralSchrader, A. J., S. Rauer-Bruening, P. J. Olbert, A. Hegele, J. Rustemeier et R. Hofmann. « Incidence and long term prognosis of papillary renal cell carcinoma ». Journal of Clinical Oncology 27, no 15_suppl (20 mai 2009) : e16020-e16020. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e16020.
Texte intégralThèses sur le sujet "Metastatic papillary renal-Cell cancer"
De, Vries-Brilland Manon. « Caractérisation du microenvironnement immunitaire des carcinomes papillaires du rein ». Electronic Thesis or Diss., Angers, 2023. http://www.theses.fr/2023ANGE0017.
Texte intégralArticle 1: Checkpoint inhibitors in metastatic papillary renal cell carcinoma : papillary Renal Cell Carcinoma (pRCC) is the most common non-clear cell RCC (nccRCC) and a distinct entity, although heterogenous, associated with poor outcomes. The treatment landscape of metastatic pRCC (mpRCC) relied so far on targeted therapies, mimicking previous developments in metastatic clear-cell renal cell carcinoma. However, antiangiogenics as well as mTOR inhibitors retain only limited activity in mpRCC. As development of immune checkpoint inhibitors (ICI) is now underway in patients with mpRCC, we aimed at discussing early activity data and potential for future therapeutic strategies in monotherapy or combination. Expression of immune checkpoints such as PD-L1 and infiltrative immune cells in pRCC could provide insights into their potential immunogenicity, although this is currently poorly described. Based on retrospective and prospective data, efficacy of ICI as single agent remains limited. Combinations with tyrosine-kinase inhibitors, notably with anti-MET inhibitors, harbor promising response rates and may enter the standard of care in untreated patients. Collaborative work is needed to refine the molecular and immune landscape of pRCC, and pursue efforts to set up predictive biomarker-driven clinical trials in these rare tumors. Article 2 : Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma. Background : papillary Renal CellCarcinoma (pRCC) is the most common non-clear cell RCC (nccRCC), and associated with poor outcomes in the metastatic setting. In this study, we aimed to comprehensively evaluate the immune tumor microenvironment (TME) ,largely unknown, of patients with metastatic pRCC and identify potential therapeutic targets. Methods : we performed quantitative gene expression analysis of TME using MCP-counter methodology, on 2 independent cohorts of localized pRCC (n=271 and n=98). We then characterized the TME, using immunohistochemistry (n=38) and RNA-sequencing (RNA-seq) (n=30) on metastatic pRCC from the prospective AXIPAP trial cohort. Results: unsupervised clustering identified 2 "TME subtypes", in each of the cohorts : the “immune-enriched” and the “immune-low”.Within AXIPAP trial cohort, the “immune-enriched” cluster was significantly associated with a worse prognosis according to the median overall survival to 8 months (95%CI, 6-29) versus 37 months (95%CI, 20-NA,p=0.001).The 2 immune signatures, Teff and JAVELIN Renal 101 Immuno signature, predictive of response to immune checkpoint inhibitors (CPI) in ccRCC, were significantly higher in the “immune-enriched” group (adjusted p<0.05). Finally, 5 differentially overexpressed genes were identified, corresponding mainly to B lymphocyte populations. Conclusion : for the first time, using RNA-seqand IHC, we have highlighted a specific immune TME subtype of metastatic pRCC, significantly more infiltrated with T and Bimmune population. This “immune-enriched” group appears to have a worse prognosis and could have a potential predictive value for response to immunotherapy, justifying the confirmation of these results in a cohort of metastatic pRCC treated with CPI and incombination with targeted therapies
Bartrolí, Comellas Mariona. « Prognostic markers and therapeutic targets for metastatic renal cell carcinoma ». Doctoral thesis, Universitat de Barcelona, 2018. http://hdl.handle.net/10803/664198.
Texte intégralRecentment, l’estudi de la metàstasi ha guanyat importància amb l’objectiu d’augmentar la supervivència dels pacients amb càncer. En el càncer renal (RCC), el descobriment de biomarcadors metastàtics i dianes terapèutiques és necessari degut a que la majoria de pacients presenten metàstasi en el moment del diagnòstic. L’objectiu d’aquesta tesi ha estat el descobriment de nous biomarcadors i dianes terapèutiques pel càncer renal metastàtic a través de dues variants d’un model animal orthoxenograft (PDOX) de RCC de cèl·lula clara (ccRCC). Els models PDOX han guanyat molta importància en l’estudi de la progressió del càncer i la metàstasi, ja que mimetitzen la histologia, la capacitat metastàtica i la resposta als tractaments. Prèviament, s’havien seqüenciat les dues variants d’aquest model PDOX tant a nivell de DNA com de RNA, juntament amb un anàlisi FISH. En primer lloc, la Carbxoxipeptidasa E (CPE), un dels gens més expressats en la variant metastàtica, ha demostrat ser important en la invasió quan és secretada al medi, tot i no ser suficient per generar metàstasi in vivo. A més, s’ha associat amb el ccRCC i anti-correlacionat amb la supervivència d’aquests pacients. En segon lloc, hem estudiat dues molècules de la cascada de coagulació, una de les més alterades en nivells de RNA. Hem demostrat que el Factor XIII (FXIII o F13) està relacionat amb CPE in vivo, malgrat que l’expressió de les dues molècules no és suficient per a que es desenvolupi la metàstasi. Tot i així, el F13 afecta la supervivència de pacients amb ccRCC, suggerint aquestes dues molècules com a possibles biomarcadors d’aquest tipus de càncer. A més, la inhibició del Receptor del Factor de Coagulació II (F2R) ha demostrat reduir les fases inicials i finals del procés metastàtic. Així doncs, l’ús d’inhibidors de F2R, juntament amb el fet que la cascada de coagulació es relaciona amb el pronòstic dels pacients, fa que aquesta tesi obri noves oportunitats per al tractament de la metàstasi i la malignització del càncer. En resum, hem descobert nous biomarcadors i dianes terapèutiques que, juntament amb futures validacions, sobretot en clínica, poden ser útils per als pacients metastàtics de ccRCC.
Perrier-Trudova, Victoria. « Molecular characterization of hereditary and sporadic papillary renal cell carcinoma type 2 (PRCC2) ». Thesis, Paris, EPHE, 2015. http://www.theses.fr/2015EPHE3085.
Texte intégralPapillary Renal Cell Carcinoma type 2 (PRCC2) is known to be a very aggressive type of kidney cancer with a high metastatic potential, poor outcome and absence of effective therapy. Hereditary form of PRCC2 is associated with rare hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is characterized by germline heterozygous mutations in the Fumarate Hydratase (FH) gene that encodes an enzyme of the Krebs cycle, Fumarase. It has been shown that the accumulation of fumarate induces activation of Hypoxia Inducible Factor (HIF) and ROS (Reactive Oxygen Species) pathways. Nevertheless, no FH gene mutation has been reported in sporadic PRCC2 tumors. The goal of this study is to better characterize hereditary and sporadic PRCC2. Our transcriptome analysis identified the set of genes that are differentially expressed between the two types of PRCC2. Subsequent immunohistochemistry screening did not reveal any potential diagnostics biomarkers. Further, the comprehensive computational analysis of gene profiling data revealed that hereditary and sporadic PRCC2 share the similar molecular signature with NRF2-KEAP1 axis deregulation as one of the major pathway in both forms. We demonstrated that over expression of Aldo-keto reductase family 1 member B10 (AKR1B10) is the direct consequence of the antioxidant response element (ARE) activation shared in hereditary and sporadic tumors. Finally, we have established FH-deficient cell line (NCCFH1) a new preclinical model of hereditary PRCC2. It presents the perfect platform for studying the metabolic features and testing new therapies for hereditary PRCC2, while bortezomib appears to be a potential efficient therapeutic option
Zastrow, Stefan, Anh Phuong, Immanuel von Bar, Vladimir Novotny, Oliver W. Hakenberg et Manfred P. Wirth. « Primary Tumor Size in Renal Cell Cancer in Relation to the Occurrence of Synchronous Metastatic Disease ». Karger, 2014. https://tud.qucosa.de/id/qucosa%3A70551.
Texte intégralAmbrosetti, Damien. « Carcinomes rénaux : caractérisation moléculaire et des voies métaboliques dépendant des mécanismes hypoxiques ». Thesis, Nice, 2015. http://www.theses.fr/2015NICE4143/document.
Texte intégralRenal carcinomas (RCC) are divided into several subtypes, defined by histological, genetic and phenotypic criteria. The differential diagnosis of these tumors is important with prognostic and therapeutic implications. Genetics and diagnosis: We studied the clinical, histological, immunohistochemical and genetic of papillary RCC (PRCC) type 1 and 2 cohort. An extensive genomic characterization completed by NGS has allowed us to classify type 2 PRCC in several groups of variable clinical evolution. Our results provide new information on the pathogenesis of PRCC that provide perspectives for personalized treatment. Metabolism, tumor grade and phenotype: In a series of clear cell RCC (ccRCC), we analyzed the characteristics of these tumors and the expression of proteins involved in the metabolism and isoforms of HIF. This study allowed us to demonstrate quantitative correlation between the expression of MCT1, GLUT1 and CA XII and Fuhrman grade, and qualitatively peripheral HIF2alpha localization and co-localization of proteins HIF2alpha and HAF. Theranostic strategies: In order to define the most appropriate treatment for patients with RCC, we made a parallel between sensitivity to targeted therapies of patients (in vivo), and cells derived from the original tumor (in vitro). We have demonstrated that the response in patients and in cells and was similar, thus in vitro assays are a way to define personalized treatment for ccRCC
Roigas, Jan. « Chemoimmuntherapie und immunologische Bedeutung von 70 kiloDalton Hitzeschockproteinen beim metastasierten Nierenzellkarzinom ». Doctoral thesis, [S.l.] : [s.n.], 2004. http://deposit.ddb.de/cgi-bin/dokserv?idn=97263438X.
Texte intégralAlbiges-Sauvin, Laurence. « Caractérisation des Carcinomes Papillaires du Rein ». Thesis, Paris 11, 2013. http://www.theses.fr/2013PA11T070.
Texte intégralPapillary renal cell carcinomas (pRCC) are the second most common form of Renal Carcinomas and belongs to the non clear cell carcinomas family. This tumour type is an heterogeneous group of tumours usually subdivided in type I and type II according to pathological features. The prognosis of pRCC in the metastatic setting is worse to clear cell carcinoma’s prognosis. Biological characteristics of pRCC are poorly known and did not allow the development of specific targeted therapies.This work first presents a synthesis of published data regarding biology, pathology, therapeutics and prognosis of pRCC. This review has been published. (Albiges et al. The Oncologist 2012)Second part is dedicated to the analysis of MET proto-oncogene across pRCC. The main focus is to assess MET activation drivers. This analysis (i) characterises MET gene DNA copy number alterations (CGH array for type II pRCC and CGMA approach for Type I pRCC) and their correlation with gene expression profiling; (ii) assess activating mutations within the tyrosine kinase of MET gene in the type I pRCC; and (iii) investigate expression level of ligand and co-activators of MET receptor. This analysis is under publication. (Albiges et al. Clinical Cancer Research)Third and last part of this work aims at identifing new biological pathway specific to pRCC using clustering of gene expression profiling and DNA abnormalities assessed by CGHarray inthe type II pRCC subtypes with matching gene expression data
GOBBO, Stefano. « CLEAR CELL-PAPILLARY RENAL CELL CARCINOMA ». Doctoral thesis, 2014. http://hdl.handle.net/11562/706768.
Texte intégralClear cell papillary renal cell carcinoma (CCPRCC) is renal neoplasm that has been recently proposed to be added to the current WHO classification of renal tumors. We collected and described a series of these neoplasms, in order to get insights to their clinico-pathological and molecular profiles. We identified 14 CCPRCC. A first level of Immunohistochemical analysis was performed using CK7, CD10, AE1/AE3, alpha-methylacyl-CoA racemase, PV, S100A1, α-SMA, caldesmon and desmin. We also performed FISH analysis using probes for chromosome 3 and 3p25, array CGH, VHL sequencing and methylation analysis on a part of the cases. Than with a second level of immunoistochemical analysis, we investigated the immunoexpression of 34βE12, CK1, CK5, CK10, CK14 and GATA3, looking for specific markers. The mean age of the patients was 61, including 9 males and 5 females. The average tumor diameter was 2,62 cm. CCPRCC presented a thick encapsulation and a tubule-papillary or tubule-cystic morphology composed of clear cells with low-grade nuclei. With the first level of immunoistochemical analyses all cases were positive for CK7 and AE1-AE3 and negative for P504S, Parvalbumin, HMB45 and cathepsin K; 75% and 62% of cases were positive respectively for CD10 and S100A1. No deletion of chromosome 3p, significant VHL methylation or changes in copy number was detected in any case, whereas only one CCPRCC showed VHL mutation and presented deletions in chromosome 3 and 6 at CGH analysis. The second level immunoistochemical analysis showed that 13 of 14 cases of CCPRCC express 34βE12. The immunoexpression of CK14 had the same result of 34βE12. All cases were negative for Ck1 and CK10; only 4 cases of CCPRCC were positive for CK5. GATA3 was expressed in 7 of 13 (54%) cases of CCPRCC. Comparing as control the immunoexpression of 292 cases of conventional clear cell RCC 34βE12 (or CK14) was expressed in 0,3% and GATA3 was expressed in 1% of the cases giving to them a strong specific meaning. We concluded that CCPRCC show strong and diffuse positivity for CK7 and do not show 3p deletion, VHL mutation or methylation abnormalities. These tumors show a genomic stability after wide whole genomic analysis. We propose the immunoistochemical markers 34βE12 (or CK14) and GATA3 as specific markers useful for the identification of these distinct renal neoplasms.
TSAI, YI-TA, et 蔡易達. « The molecular mechanisms of Sorafenib and GW5074 anti-cancer combination therapy in metastatic renal cell carcinoma ». Thesis, 2017. http://ndltd.ncl.edu.tw/handle/51617077893198827872.
Texte intégral國防醫學院
醫學科學研究所
105
Mitochondria are the powerhouses of cells and targets of cancer therapeutics. The unique role of Raf proteins in the mitochondria provides a strong rationale to target mitochondrial Raf proteins. However, Raf inhibitor monotherapy induces serine 338 phosphorylation of C-Raf (pC-RafS338) subsequent to mitochondrial translocation and impedes therapy. Currently, no selective mitochondrial targeted cancer therapeutics is available. This study identified a unique combination therapy of Raf inhibitors, sorafenib and GW5074, and targeted mitochondrial function instead of the canonical Raf signalling pathway, irrespective of upstream Ras and Raf mutation status. The GW5074 was bound to C-Raf and induced C-Raf conformation change, which enhanced sorafenib binding. This drug-target interaction facilitated the S308 phosphorylation of DAPK (pDAPKS308) translocation from the mitochondria to the cytoplasm, causing mitochondrial dysfunction and ROS generation. ROS facilitated PP2A dephosphorylation of DAPK at serine 308, disassembled the C-Raf and DAPK complex in the cytoplasm, and induced profound cancer cells necroptosis.
Livres sur le sujet "Metastatic papillary renal-Cell cancer"
Wong, Han Hsi, Basma Greef et Tim Eisen. Treatment of metastatic renal cancer. Sous la direction de James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0089.
Texte intégralEisen, Tim. The patient with renal cell cancer. Sous la direction de Giuseppe Remuzzi. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199592548.003.0172.
Texte intégralChapman, Hannah, et Christine Elwell. Renal and bladder cancer. Sous la direction de Patrick Davey et David Sprigings. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199568741.003.0167.
Texte intégralJafri, Mariam, et Eamonn R. Maher. Genetics and molecular biology of renal cancer. Sous la direction de James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0084.
Texte intégralCassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff et Madhumita Bhattacharyya. Gynaecological cancers. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0020_update_001.
Texte intégralChapitres de livres sur le sujet "Metastatic papillary renal-Cell cancer"
Mulders, Peter F. « Treatment Strategies in Metastatic Renal Cell Carcinoma ». Dans Renal Cancer, 343–59. Totowa, NJ : Humana Press, 2001. http://dx.doi.org/10.1385/1-59259-144-2:343.
Texte intégralPowles, Tom, et Axel Bex. « Integration of Surgery in Metastatic Renal Cancer ». Dans Renal Cell Carcinoma, 257–77. Totowa, NJ : Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-062-5_15.
Texte intégralVives Dilme, Roser, Juan Gómez Rivas, Riccardo Campi, Javier Puente et Jesús Moreno Sierra. « Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma ». Dans Robotic Surgery for Renal Cancer, 237–45. Cham : Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-11000-9_24.
Texte intégralBranscheid, D., S. Pomer, S. Krysa et I. Vogt-Moykopf. « Survival After Lung Surgery for Metastatic Renal Cancer ». Dans Contemporary Research on Renal Cell Carcinoma, 30–38. Berlin, Heidelberg : Springer Berlin Heidelberg, 1994. http://dx.doi.org/10.1007/978-3-642-78609-9_4.
Texte intégralMatrana, Marc, Bradley Atkinson et Nizar M. Tannir. « Combinatorial and Sequential Targeted Therapy in Metastatic Renal Cell Carcinoma ». Dans Kidney Cancer, 225–39. Berlin, Heidelberg : Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-21858-3_15.
Texte intégralMatrana, Marc R., Bradley J. Atkinson et Nizar M. Tannir. « Combinatorial and Sequential Targeted Therapy in Metastatic Renal Cell Carcinoma ». Dans Kidney Cancer, 315–34. Cham : Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-17903-2_19.
Texte intégralBergerot, Paulo, Kathy Burns, Dhruv Prajapati, Rachel Fox, Meghan Salgia et Sumanta K. Pal. « Advances in the Treatment of Metastatic Renal Cell Carcinoma ». Dans Cancer Treatment and Research, 127–37. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93339-9_6.
Texte intégralBollack, C., D. Jacqmin, J. P. Bergerat, J. Ford, R. Herbrecht, P. Dufour, F. Oberling, G. Prevost, P. Salze et J. Jurascheck. « Recombinant Interferon Alpha Plus Vinblastine in Metastatic Renal Cell Cancer : Updated Results ». Dans Immunotherapy of Renal Cell Carcinoma, 75–81. Berlin, Heidelberg : Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-75853-9_12.
Texte intégralChilds, Richard W., et Cristian A. Carvallo. « Allogeneic Hematopoietic Blood-Cell Transplantation As Immunotherapy for Metastatic Renal Cell Carcinoma ». Dans Cancer Immunotherapy at the Crossroads, 279–93. Totowa, NJ : Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-743-7_15.
Texte intégralRyan, Charles J. « Developments in the Management of Genitourinary Malignancies : Prostate Cancer and Renal Cell Carcinoma ». Dans From Local Invasion to Metastatic Cancer, 533–44. Totowa, NJ : Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-087-8_44.
Texte intégralActes de conférences sur le sujet "Metastatic papillary renal-Cell cancer"
Li, Fang, Qiuyu Jiang, Jinyuan Zhang, Xintao Jing, Xiaofei Wang et Chen Huang. « Pan-cancer analysis of CDCA2 and its function in papillary renal cell carcinoma ». Dans ICBBT 2022 : 2022 14th International Conference on Bioinformatics and Biomedical Technology. New York, NY, USA : ACM, 2022. http://dx.doi.org/10.1145/3543377.3543391.
Texte intégralKim, Ji-Yeon, Se-Hoon Lee, Jong-Il Kim, Jong-Yeon Shin et Dae seog Heo. « Abstract 1888 : Target sequencing of papillary renal cell carcinoma, type 2, using custom-made kidney cancer panel ». Dans Proceedings : AACR Annual Meeting 2014 ; April 5-9, 2014 ; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-1888.
Texte intégralYao, Qian, Jianfeng Li et Dexi Liu. « Abstract 4412 : Combining cytokine gene therapy with conventional cancer chemotherapyfor treatment of metastatic renal cell carcinoma ». Dans Proceedings : AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012 ; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-4412.
Texte intégralRoseweir, Antonia K., Tahir Qayyum, Robert Jones, Grenville Oades, Michael Aitchison et Joanne Edwards. « Abstract 14 : The effect of Src family kinase inhibitors in non-metastatic clear cell renal cancer. » Dans Proceedings : AACR 104th Annual Meeting 2013 ; Apr 6-10, 2013 ; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-14.
Texte intégralKhandelwal, Jaanki, Devaki S. Surasi, Sergio P. Klimkowsky, Nathaniel Wilson, Mohammad J. Moussa, Matthew Campbell, Amishi Shah et al. « 523 Nivolumab and ipilimumab in patients with metastatic non-clear cell renal cell carcinoma at MD Anderson Cancer Center ». Dans SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.0523.
Texte intégralBeom, Seung-Hoon, Sejung Park, Woo Sun Kwon, Sang Joon Shin, Soo-Youl Kim, Nam Hoon Cho et Sun Young Rha. « Abstract A053 : Significance of Transglutaminase 2 expression on clinical outcome in metastatic renal cell carcinoma ». Dans Abstracts : AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics ; October 26-30, 2019 ; Boston, MA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1535-7163.targ-19-a053.
Texte intégralFarace, Françoise, Marine Gross - Goupil, Elodie Tournay, Melissa Taylor, Catherine Hill et Bernard Escudier. « Abstract 372 : Circulating endothelial progenitor cell levels predict survival benefit in metastatic renal cell cancer patients treated with antiangiogenic agents ». Dans Proceedings : AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010 ; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-372.
Texte intégralSeok, Han Kyung, Raven Peter, Awrey Shannon, Li Estelle, Fazli Ladan, Gleave Martin et So Alan. « Abstract A36 : Knockdown of integrin-linked kinase reduces invasive and metastatic potential of renal cell carcinoma ». Dans Abstracts : AACR Special Conference : The Translational Impact of Model Organisms in Cancer ; November 5-8, 2013 ; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1557-3125.modorg-a36.
Texte intégralHarris, Wayne B., Dana C. Nickleach, Yuan Liu, Omer Kucuk et Viraj A. Master. « Abstract C15 : Inflammation-free survival as a surrogate endpoint for overall survival in patients with metastatic renal cell carcinoma ». Dans Abstracts : Sixth AACR Conference : The Science of Cancer Health Disparities ; December 6–9, 2013 ; Atlanta, GA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7755.disp13-c15.
Texte intégralBensalem, Assia, et Kamel Bouzid. « Abstract B202 : Hand-foot syndrome, the main side effect of patients with metastatic renal cell carcinoma treated with sunitinib. » Dans Abstracts : AACR-NCI-EORTC International Conference : Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013 ; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-b202.
Texte intégral